The prostate cancer patient had higher C-reactive protein than BPH patient

Korean Journal of Urology

Volumn 54, Issue 2, 2013, Pages 85-88

  Kim, Youngjun ^a   Jeon, Yongseok ^a   Lee, Hana ^a   Lee, Donghyun ^a   Shim, Bongsuk ^a  

^a Ewha Womans University School of Medicine   (South Korea)

Author keywords

C reactive protein; Prostate specific antigen; Prostatic neoplasms

Indexed keywords

C REACTIVE PROTEIN;

ADULT; AGED; ARTICLE; CANCER STAGING; DISEASE CLASSIFICATION; HUMAN; IMMUNOASSAY; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; METASTASIS; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE HYPERTROPHY; RETROSPECTIVE STUDY; TUMOR GROWTH;

EID: 84874289940     PISSN: 20056737     EISSN: 20056745     Source Type: Journal    
DOI: 10.4111/kju.2013.54.2.85     Document Type: Article

References (14)

1. Lee S, Choe JW, Kim HK, Sung J. High-sensitivity C-reactive protein and cancer. J Epidemiol 2011;21:161-8.
2. Elsberger B, Lankston L, McMillan DC, Underwood MA, Edwards J. Presence of tumoural C-reactive protein correlates with progressive prostate cancer. Prostate Cancer Prostatic Dis 2011;14:122-8.
3. Platz EA, De Marzo AM. Epidemiology of inflammation and prostate cancer. J Urol 2004;171(2 Pt 2):S36-40.
4. Saito K, Kihara K. C-reactive protein as a biomarker for urological cancers. Nat Rev Urol 2011;8:659-66.
5. Dubey S, Vanveldhuizen P, Holzbeierlein J, Tawfik O, Thrasher JB, Karan D. Inflammation-associated regulation of the macrophage inhibitory cytokine (MIC-1) gene in prostate cancer. Oncol Lett 2012;3:1166-70.
6. Salman H, Ori Y, Bergman M, Djaldetti M, Bessler H. Human prostate cancer cells induce inflammatory cytokine secretion by peripheral blood mononuclear cells. Biomed Pharmacother 2012;66:330-3.
7. Mengus C, Le Magnen C, Trella E, Yousef K, Bubendorf L, Provenzano M, et al. Elevated levels of circulating IL-7 and IL-15 in patients with early stage prostate cancer. J Transl Med 2011;9:162.
8. Lucia MS, Torkko KC. Inflammation as a target for prostate cancer chemoprevention: pathological and laboratory rationale. J Urol 2004;171(2 Pt 2):S30-4.
9. Lehrer S, Diamond EJ, Mamkine B, Droller MJ, Stone NN, Stock RG. C-reactive protein is significantly associated with prostate-specific antigen and metastatic disease in prostate cancer. BJU Int 2005;95:961-2.
10. Gupta S, Adhami VM, Subbarayan M, MacLennan GT, Lewin JS, Hafeli UO, et al. Suppression of prostate carcinogenesis by dietary supplementation of celecoxib in transgenic adenocarcinoma of the mouse prostate model. Cancer Res 2004;64:3334-43.
11. McCall P, Catlow J, McArdle PA, McMillan DC, Edwards J. Tumoral C-reactive protein and nuclear factor kappa-B expression are associated with clinical outcome in patients with prostate cancer. Cancer Biomark 2011-2012;10:91-9.
12. Ito M, Saito K, Yasuda Y, Sukegawa G, Kubo Y, Numao N, et al. Prognostic impact of C-reactive protein for determining overall survival of patients with castration-resistant prostate cancer treated with docetaxel. Urology 2011;78:1131-5.
13. Beer TM, Lalani AS, Lee S, Mori M, Eilers KM, Curd JG, et al. C-reactive protein as a prognostic marker for men with androgen-independent prostate cancer: results from the ASCENT trial. Cancer 2008;112:2377-83.
14. Latif Z, McMillan DC, Wallace AM, Sattar N, Mir K, Jones G, et al. The relationship of circulating insulin-like growth factor 1, its binding protein-3, prostate-specific antigen and C-reactive protein with disease stage in prostate cancer. BJU Int 2002;89:396-9.